Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1324
Shown on this page
12
Current sort
Recently updated
Campus scope
Dana-Farber Cancer Institute, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Dana-Farber Cancer Institute, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 505–516 of 1,324 matching trials with a site at Dana-Farber Cancer Institute, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653
Status at this site: Recruiting
View directory record Official record
Conditions
CTCL
Interventions
PTX-100
Drug
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
Site status not listed — check the official record
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 1 Interventional

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871
Status at this site: Recruiting
View directory record Official record
Conditions
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Interventions
IAM1363
Drug
Lead sponsor
Iambic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

NCT06561360
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Vemurafenib, Obinutuzumab, Cladribine, Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

NCT04033497
Status at this site: Recruiting
View directory record Official record
Conditions
Brain Tumor
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 1 Interventional

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005
Status at this site: Recruiting
View directory record Official record
Conditions
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Active, not recruiting Phase 1 Interventional

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
SEA-CD70, azacitidine, Venetoclax
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

NCT05774899
Status at this site: Recruiting
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Interventions
CB-103, Abemaciclib, Lenvatinib
Drug
Lead sponsor
Michael J. Dennis, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

NCT07286292
Status at this site: Recruiting
View directory record Official record
Conditions
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Interventions
Vorasidenib
Drug
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

NCT07132190
Status at this site: Recruiting
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 1:37 PM EDT

About this Dana-Farber Cancer Institute institution page

What this page lists
ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Dana-Farber Cancer Institute at any site, browse by condition, or browse by U.S. city.